Dr Jeff Sharman - How I Treat My Patients With... - CLL Support

CLL Support

24,057 members40,920 posts

Dr Jeff Sharman - How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

AussieNeil profile image
AussieNeilPartnerAdministrator
5 Replies

In this one page overview from Clinical Care Options Oncology March 2015 (free membership), Dr Sharman explains how he categorises fit and otherwise healthy patients into low, intermediate and high treatment risk categories and chooses what he considers is the appropriate treatment for each category:

clinicaloptions.com/Oncolog...

Of particular note: "Those patients with the most favorable risk profile include those with IgHV-mutated CLL without del(17p) or del(11q) by FISH analysis and without mutations in TP53, SF3B1, and NOTCH1 by sequencing analysis. This subset represents 20% of all treated patients; when treated with FCR the progression-free survival rate in this group at 8 years approaches 70% to 80%. Although many patients with CLL are not suitable for intensive chemoimmunotherapy with FCR, this population likely derives the best outcome with this treatment." (My emphasis)

Personally, I think Dr Sharman would have been disappointed with the minimal discussion his article generated.

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
5 Replies
Fant1924 profile image
Fant1924

Seems that one must be a medical professional in order to join.

AussieNeil profile image
AussieNeilPartnerAdministrator in reply toFant1924

I've just checked my Clinical Care Options profile and bearing in mind that you only have to provide information for the starred fields, in the Degree field I've entered 'Other' and in the Speciality field I've entered 'None'.

Note that in the comments section it states: "Comments are allowed only from healthcare professionals who are registered members of Clinical Care Options." so naturally, I've never left comments.

You can nominate for email updates (along with update frequency' on the following topics: Cardiology, Hematology, Hepatitis B, Hepatitis C, HIV, Immunology, Neurology, Oncology, Transplantation and Urology.

I've nominated Hematology and Oncology, but other topics may also be of interest.

Where are you prevented from joining?

Neil

Cllcanada profile image
CllcanadaTop Poster CURE Hero

The lack of responses speaks volumes on CCO, and should not be reflective of Dr. Sharman or his extensive expertise...

~chris

AussieNeil profile image
AussieNeilPartnerAdministrator in reply toCllcanada

Good point, which emphasises the importance of seeing a haematologist (particularly one experienced with CLL) rather than an oncologist when you have CLL...

ShariS profile image
ShariS

I agree & appreciate your sharing this. The first thing mentioned when dx'd by 1 Onc/Hem & 2 specialists is "you're lucky you're so young & healthy...". I'm moderate risk & completed 6 months FCR last year. My platelets are higher than they've been in 5 years, a 17.5 cm mass largely dissolved & I feel better than I have in at least 5 years (while dx'd only 3 years ago). I stay away from many online groups now as there is almost a chemo-shaming mantra amongst many, including & esp among those in W&W. It is nice to see evidence that there's some validity to this "old" SOC. :)

Not what you're looking for?

You may also like...

ASH 2012 Interview: Dr Jeff Sharman "Why New CLL Treatments Supersede FCR"

Dr Sharman's blog http://www.cll-nhl.com, is well worth keeping an eye on for pertinent but easily...
AussieNeil profile image
Partner

News - Acalabrutinib approved for Restricted use in Scotland

Following an abbreviated and full submissions, the Scottish Medicines Consortium has approved...
Jm954 profile image
Administrator

FCR may CURE some of us - Dr Sharman

"In today's CLL climate, web informed patients are rebelling against FCR - and in many cases, I...
AussieNeil profile image
Partner

Scottish Medicines Agency has decided in favour of Venetoclax plus Obintuzumab for some patients.

The SMC has accepted venetoclax in combination with obinutuzumab for use in certain patients. There...
Jm954 profile image
Administrator

The CLL Treatment Revolution - Jeff Sharman

This short article on the CLL treatment revolution for relapsed CLL by Dr Jeff Sharman for Clinical...
AussieNeil profile image
Partner